People: Abraxis Bioscience, Inc. (ABII.O)

ABII.O on Nasdaq

35.22USD
9 Feb 2010
Price Change (% chg)

$-3.18 (-8.28%)
Prev Close
$38.40
Open
$38.41
Day's High
$38.63
Day's Low
$34.80
Volume
165,354
Avg. Vol
86,350
52-wk High
$73.98
52-wk Low
$24.52

view people for:

Summary

Name Age Since Current Position
Soon-Shiong, Patrick 56 2009 Executive Chairman of the Board; Chief Executive Officer of Abraxis Health
Wendel, Bruce 55 2010 Vice Chairman of the Board, Chief Executive Officer
Fogelman, Mitchell 2010 Chief Financial Officer
Hedley, Mary 44 2009 Executive Vice President - Operations, Chief Scientific Officer
Chen, David 60 2007 Director
Nimer, Stephen 55 Director
Shapiro, Leonard 80 2007 Director
Calhoun, Kirk 65 2007 Director
Sitrick, Michael 60 2009 Director
» Insider Trading

Biographies

Name Description
Soon-Shiong, Patrick Dr. Patrick Soon-Shiong, M.D. has served as Executive Chairman of the Board of Abraxis BioScience, Inc. and Chief Executive Officer of Abraxis Health since April 30, 2009. Prior to that, Dr. Soon-Shiong served as chairman and chief executive officer from the separation from old Abraxis BioScience (“Old Abraxis”) in November 2007 until April 2009. Dr. Soon-Shiong also served as chief executive officer of APP Pharmaceuticals, Inc. (“New APP”), the successor to Old Abraxis, from November 2007 through May 2008 and served as the chairman of New APP from the separation until the acquisition of New APP by Fresenius SE in September 2008. He was also the chairman and chief executive officer of Old Abraxis from April 2006 through November 2007. Dr. Soon-Shiong received the 2006 Gilda Club Award for the advancement of cancer medicine and is a recipient of a 2007 Ellis Island Medal of Honor, the Caritas Award from St. John’s Health Center and the 2007 Lifetime Achievement Award from St. Mary’s Medical Center. He is a co-inventor of over 50 issued United States patents and has published more than 100 scientific papers. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Soon-Shiong is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada. Dr. Soon-Shiong serves on the Board of Directors for the National Institute of Transplantation, the Technology Council for the Center for Cancer Nanotechnology Excellence at Northwestern University, two advisory boards of the RAND Corporation (the Health Board and the Asia Pacific Policy Board), the President’s Council at the RAND Corporation, the Board of Trustees for the Saint John’s Health Center and the Board of the California NanoSystems Institute at UCLA.
Wendel, Bruce Mr. Bruce Wendel serves as Executive Vice President - Corporate Operations and Development, Director of Abraxis BioScience, Inc. Mr. Wendel previously served as executive vice president of corporate development at Old Abraxis from April 2006 to November 2007. From August 2004 to April 2006, Mr. Wendel was the vice president of corporate development for Old APP. From August 2002 to August 2004, he served as vice president, business development and licensing for IVAX Corporation, a multinational company engaged in the research, development, manufacture and marketing of pharmaceutical products. From August 1988 to December 1989, Mr. Wendel served as in-house counsel for Bristol-Myers Squibb, a global biopharmaceutical company and related health care products company, before shifting to business and corporate development from January 1990 to August 2002. Previously, Mr. Wendel also held positions in the legal departments of consumer products companies Playtex and Combe. He earned a J.D. degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. degree from Cornell University.
Fogelman, Mitchell Mr. Mitchell K. Fogelman serves as Chief Financial Officer of Abraxis BioScience, Inc. Mr. Fogelman joined Abraxis BioScience in October 2009 as Senior Vice President of Finance. Prior to Abraxis BioScience, Mr. Fogelman served as Senior Vice President of Finance, Chief Financial Officer and Treasurer of CytRx Corporation, a Nasdaq-listed biopharmaceutical research and development company, from September 2007 to December 2008. From 1982 to 2007, Mr. Fogelman worked at International Aluminum Corporation, a NYSE-listed manufacturer of commercial and residential building products, last serving as Senior Vice President-Finance, Chief Financial Officer and Corporate Secretary from June 2000 to August 2007. Mr. Fogelman is a CPA who worked at PricewaterhouseCoopers LLP from 1975 to 1982. He earned his M.B.A. in finance and quantitative analysis from the Anderson School of Management at the University of California, Los Angeles, and his B.A. degree in mathematics from the University of California, Los Angeles.
Hedley, Mary Dr. Mary Lynne Hedley, Ph.D. is Executive Vice President - Operations, Chief Scientific Officer of Abraxis BioScience, Inc. Dr. Hedley most recently served as Executive Vice President of Eisai Corporation of North America following Eisai's acquisition of MGI PHARMA INC. where she had served as Executive Vice President and Chief Scientific Officer since 2005. She joined MGI PHARMA in 2004 as Senior Vice President and General Manager. Previously, Dr. Hedley co-founded ZYCOS, Inc., a biotechnology company, and held roles of progressively greater responsibility ultimately to her serving as the company's President and Chief Executive Officer. Dr. Hedley's early research career consisted of two consecutive postdoctoral fellowships at Harvard University from 1989 through 1996. She earned her bachelor of science degree in Microbiology from Purdue University and her doctorate degree in Immunology from the University of Texas, Southwestern Medical Center. She is a named inventor on multiple patents in the field of immunology, and has been widely published in a variety of peer-reviewed journals. Dr. Hedley is the recipient of multiple awards and fellowships, is a frequent guest lecturer, and an active volunteer in educational as well as local community organizations.
Chen, David Dr. David S. Chen, Ph.D. has served as a director of Abraxis BioScience, Inc. since the separation in November 2007. Dr. Chen previously served as a director of Old Abraxis from June 1998 to the date of the separation. Dr. Chen has been a senior executive vice president of China Development Industrial Bank since February 2004. Dr. Chen also served as president of China Trust Venture Capital Corporation from October 2001 to May 2004 and was the chairman of Cypac Investment Management Limited from 1998 to 2001. He served as Central Investment Holdings Company’s chief executive officer from July 1996 to February 2000, and chief financial officer from May 1991 to February 1994. Dr. Chen holds a B.S. in agricultural economics from National Taiwan University, a M.B.A. from California State University at Long Beach and a Ph.D. in business administration from Nova University, Florida.
Nimer, Stephen Dr. Stephen D. Nimer, M.D. has served as a director of Abraxis BioScience, Inc. since the separation in November 2007. Dr. Nimer previously served as a director of Old Abraxis from May 2001 to the date of the separation. Dr. Nimer has been the Chief of the Hematology Service at Memorial Sloan-Kettering Cancer Center since 1993, and Vice Chairman for Faculty Development since 2008. He was head of the Division of Hematologic Oncology from 1996 to 2008. He has also taught medicine at the Cornell University School of Medicine since 1993. Dr. Nimer holds a M.D. from the University of Chicago and a B.S. in biology from Massachusetts Institute of Technology.
Shapiro, Leonard Leonard Shapiro has served as a director of Abraxis BioScience, Inc. since the separation in November 2007. Mr. Shapiro previously served as a director of Old Abraxis from July 2002 to the date of the separation. He has more than 50 years of business experience as an entrepreneur and founder of Shapco, Inc., a manufacturer and distributor of pipe products, where he has been the chief executive officer since 1960. As chief executive officer of Shapco, Inc., he presided over the firm’s real estate investment activities in addition to the manufacturing and distribution operations. Shapco, Inc., together with its subsidiaries, employs over 300 employees in various locations throughout the western United States.
Calhoun, Kirk Kirk K. Calhoun has served as a director of Abraxis BioScience, Inc. since the separation in November 2007. Mr. Calhoun previously served as a director of Old Abraxis from 2002 to the date of the separation. He joined Ernst & Young LLP in 1965 and served as a partner of the firm from 1975 until his retirement in June 2002 where his responsibilities included both area management and serving clients in a variety of industries. Mr. Calhoun is a certified public accountant with a background in auditing and accounting. Mr. Calhoun is also currently a director of Response Genetics, Inc. Mr. Calhoun holds a B.S. in accounting from the University of Southern California.
Sitrick, Michael Mr. Michael S. Sitrick serves as Director of Abraxis BioScience, Inc. He is the chairman and chief executive officer of Sitrick Brincko LLC, a wholly-owned subsidiary of Resources Connection, Inc. Sitrick Brincko is a strategic communications, corporate advisory and restructuring firm and is also the successor firm to Sitrick And Company, one of the nation’s strategic public relations firms. Prior to forming Sitrick and Company in 1989, Mr. Sitrick served as senior vice president—communications for Wickes Companies, Inc. and a member of that company’s senior management group from 1981 to 1989. Before joining Wickes, Mr. Sitrick headed corporate communications and advertising for National Can Corporation, was a Group Supervisor for a Chicago public relations firm and served as an assistant director of public information in the Richard J. Daley administration in Chicago. Mr. Sitrick previously served as a director of old Abraxis BioScience from August 2006 until November 2007 when that company was separated into two independent public companies—the current Abraxis BioScience and APP Pharmaceuticals, Inc.—and as a director of APP Pharmaceuticals from November 2007 until September 2008 when that company was sold to Fresenius SE. He holds a B.S. degree in business administration and journalism from the University of Maryland, College Park.

Basic Compensation

Name Fiscal Year Total
Soon-Shiong, Patrick 3,450,410
Wendel, Bruce 714,362
Fogelman, Mitchell --
Hedley, Mary --
Chen, David --
Nimer, Stephen --
Shapiro, Leonard --
Calhoun, Kirk --
Sitrick, Michael --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
SOON SHIONG PATRICK 894 $41.17
WENDEL BRUCE J 239 $41.17
WENDEL BRUCE J 797 $35.42
SOON SHIONG PATRICK 5,758,758 $0.00
SOON SHIONG PATRICK 23,035,031 $0.00
SOON SHIONG PATRICK 5,758,758 $0.00
SOON SHIONG PATRICK 5,758,758 $0.00
SOON SHIONG PATRICK 5,758,757 $0.00
SOON SHIONG PATRICK 229,120 $0.00
SOON SHIONG PATRICK 776,107 $0.00
SOON SHIONG PATRICK 546,987 $0.00
SOON SHIONG PATRICK 23,035,031 $0.00
SOON SHIONG PATRICK 19,700,551 $0.00
SOON SHIONG PATRICK 29,954 $0.00
SOON SHIONG PATRICK 3,304,526 $0.00
O TOOLE DAVID D 319 $58.54
WENDEL BRUCE J 920 $0.00
SOON SHIONG PATRICK 732 $58.54
O TOOLE DAVID D 866 $0.00
GEEHR EDWARD C 350 $58.54
SOON SHIONG PATRICK 2,045 $0.00
WENDEL BRUCE J 329 $58.54
GEEHR EDWARD C 920 $0.00
GEEHR EDWARD C 304 $0.00
SOON SHIONG PATRICK 519 $70.40
» Full list on Insider Trading
view people for: